nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexbrompheniramine—HRH1—Histamine receptors—HRH3—attention deficit hyperactivity disorder	0.147	0.161	CbGpPWpGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.04	0.0438	CbGpPWpGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0392	0.0429	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0336	0.0368	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0329	0.0361	CbGpPWpGaD
Dexbrompheniramine—Captodiame—DRD3—attention deficit hyperactivity disorder	0.0307	0.349	CrCbGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0237	0.026	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0228	0.025	CbGpPWpGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0221	0.0242	CbGpPWpGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0214	0.0234	CbGpPWpGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.021	0.023	CbGpPWpGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0207	0.0227	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0199	0.0219	CbGpPWpGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0193	0.0212	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0185	0.0203	CbGpPWpGaD
Dexbrompheniramine—KCNH2—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.0181	0.0198	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.018	0.0197	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.0177	0.0194	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0174	0.0191	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.0162	0.0178	CbGpPWpGaD
Dexbrompheniramine—KCNH2—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.0147	0.0161	CbGpPWpGaD
Dexbrompheniramine—HRH1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.0135	0.0148	CbGpPWpGaD
Dexbrompheniramine—Chlorphenamine—SLC6A3—attention deficit hyperactivity disorder	0.0129	0.147	CrCbGaD
Dexbrompheniramine—KCNH2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.0127	0.0139	CbGpPWpGaD
Dexbrompheniramine—KCNH2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.0118	0.0129	CbGpPWpGaD
Dexbrompheniramine—KCNH2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.0118	0.0129	CbGpPWpGaD
Dexbrompheniramine—HRH1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0114	0.0125	CbGpPWpGaD
Dexbrompheniramine—Chlorphenamine—SLC6A4—attention deficit hyperactivity disorder	0.00962	0.11	CrCbGaD
Dexbrompheniramine—Promazine—DRD4—attention deficit hyperactivity disorder	0.00939	0.107	CrCbGaD
Dexbrompheniramine—KCNH2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00925	0.0101	CbGpPWpGaD
Dexbrompheniramine—KCNH2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00886	0.00971	CbGpPWpGaD
Dexbrompheniramine—KCNH2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00855	0.00937	CbGpPWpGaD
Dexbrompheniramine—KCNH2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00796	0.00872	CbGpPWpGaD
Dexbrompheniramine—Promazine—DRD1—attention deficit hyperactivity disorder	0.00795	0.0905	CrCbGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00772	0.00846	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00756	0.00829	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00751	0.00823	CbGpPWpGaD
Dexbrompheniramine—KCNH2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.0074	0.00811	CbGpPWpGaD
Dexbrompheniramine—Promazine—ADRA2A—attention deficit hyperactivity disorder	0.00738	0.0841	CrCbGaD
Dexbrompheniramine—KCNH2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00722	0.00792	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00661	0.00725	CbGpPWpGaD
Dexbrompheniramine—KCNH2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00659	0.00723	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00648	0.0071	CbGpPWpGaD
Dexbrompheniramine—KCNH2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.0056	0.00614	CbGpPWpGaD
Dexbrompheniramine—Promazine—DRD2—attention deficit hyperactivity disorder	0.0056	0.0638	CrCbGaD
Dexbrompheniramine—KCNH2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00557	0.0061	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00524	0.00574	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00503	0.00552	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00493	0.00541	CbGpPWpGaD
Dexbrompheniramine—HRH1—IL-4 Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00484	0.0053	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00458	0.00502	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00449	0.00492	CbGpPWpGaD
Dexbrompheniramine—Promazine—HTR2A—attention deficit hyperactivity disorder	0.00433	0.0493	CrCbGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00426	0.00467	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00424	0.00465	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00412	0.00452	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00405	0.00444	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.004	0.00439	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00392	0.0043	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00385	0.00422	CbGpPWpGaD
Dexbrompheniramine—KCNH2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00383	0.0042	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00373	0.00409	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00365	0.004	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00353	0.00387	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00347	0.00381	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00343	0.00376	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00342	0.00375	CbGpPWpGaD
Dexbrompheniramine—HRH1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00338	0.0037	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.0032	0.0035	CbGpPWpGaD
Dexbrompheniramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00302	0.00331	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00299	0.00328	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00284	0.00312	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00279	0.00306	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00278	0.00305	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00269	0.00295	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00264	0.0029	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00261	0.00286	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00261	0.00286	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00258	0.00283	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00253	0.00277	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00243	0.00267	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00228	0.00249	CbGpPWpGaD
Dexbrompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00224	0.00245	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00193	0.00212	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00178	0.00195	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00175	0.00192	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.0017	0.00187	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00169	0.00185	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00157	0.00172	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00153	0.00168	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00153	0.00167	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00152	0.00167	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.0015	0.00164	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00149	0.00164	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00148	0.00162	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00147	0.00161	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00143	0.00156	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00138	0.00151	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00138	0.00151	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00136	0.00149	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00134	0.00147	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00125	0.00137	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00104	0.00114	CbGpPWpGaD
Dexbrompheniramine—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000963	0.00106	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000906	0.000993	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000875	0.000959	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000842	0.000923	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000816	0.000894	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000802	0.000879	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000792	0.000868	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000738	0.000809	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000517	0.000566	CbGpPWpGaD
Dexbrompheniramine—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000274	0.0003	CbGpPWpGaD
